Weigh risks and benefits of aspirin in the secondary or primary prevention of cardiovascular events in elderly individuals

Author： Adis International Limited

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.20, Iss.8, 2004-08, pp. : 8-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aspirin for the Prevention of Cardiovascular Events in the Elderly

By Mahé I.

Drugs & Aging, Vol. 20, Iss. 13, 2003-01 ,pp. : 999-1010

Adis International

Access to resources Recommend Favorite

Aspirin for Primary Prevention of Cardiovascular Events in the Elderly: Current Status and Future Directions

By Ward Stephanie A. Demos Lisa

Drugs & Aging, Vol. 29, Iss. 4, 2012-04 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly: Aspirin in Reducing Events in the Elderly (ASPREE)

By Nelson M.R. Reid C.M.

Drugs & Aging, Vol. 20, Iss. 12, 2003-01 ,pp. : 897-903

Adis International

Access to resources Recommend Favorite

Aspirin Use for the Primary Prevention of Cardiovascular Disease in the Elderly

By Sarbacker G. Blair Lusk Kathleen A. Flieller Lauren A. Van Liew Jeffrey R.

The Consultant Pharmacist, Vol. 31, Iss. 1, 2016-01 ,pp. : 24-32

American Society of Consultant Pharmacists

Access to resources Recommend Favorite

Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events

By Plosker Greg L. Lyseng-Williamson Katherine A.

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1031-1053

Adis International

Access to resources Recommend Favorite